Newly-discovered protein could play key role in fighting obesity
An unexpected finding about a protein that’s highly expressed in fat tissue could lead to new approaches for addressing obesity and many other diseases.
This discovery, the scientists say, could lead to new approaches for addressing obesity and potentially many other diseases.
The signalling protein known as progesterone receptor membrane component 2 (PGRMC2) had previously been detected in the uterus, liver and several areas of the body. But the lab of Enrique Saez, PhD, saw that it was most abundant in fat tissue, particularly in brown fat, which turns food into heat to maintain body temperature.
The team built on their discovery, finding that PGRMC2 binds to and releases an essential molecule called heme, which travels within cells to enable crucial life processes such as cellular respiration, cell proliferation, cell death and circadian rhythms. Saez and his team found that PGRMC2 is a ‘chaperone’ of heme, encapsulating the molecule and transporting it from the cell’s mitochondria, where heme is created, to the nucleus, where it helps carry out important functions. Without a protective chaperone, heme would react with and destroy everything in its path.
Through studies involving mice, the scientists established PGRMC2 as the first intracellular heme chaperone to be described in mammals.
They also sought to find out what happens in the body if this protein doesn’t exist to transport heme and they discovered that without PGRMC2 present in their fat tissues, mice that were fed a high-fat diet became intolerant to glucose and insensitive to insulin. By contrast, obese-diabetic mice that were treated with a drug to activate PGRMC2 function showed a substantial improvement of symptoms associated with diabetes.
“We saw the mice get better, becoming more glucose tolerant and less resistant to insulin,” Saez said. “Our findings suggest that modulating PGRMC2 activity in fat tissue may be a useful pharmacological approach for reverting some of the serious health effects of obesity.”
Saez believes it’s possible that activating the heme chaperone in other organs (including the liver, where a large amount of heme is made) could help mitigate the effects of other metabolic disorders such as non-alcoholic steatohepatitis (NASH), which is a major cause of liver transplantation today.
“We’re curious to know whether this protein performs the same role in other tissues where we see defects in heme that result in disease,” Saez said.
The study was published in Nature.